The list below displays information about clinical trials sponsored by Ipsen.
Only interventional studies that have started within the last 20 years and completed within the 2 last years will be displayed.
The study results will be available on ClinicalTrials.gov from 12 months after the end of the study.
Filters
Condition
Status
Phase
Country
Showing : 1 – 5 of 152 clinical trials
Gastroenteropancreatic Neuroendocrine Tumors
satoreotide trizoxetan
Switzerland
Completed
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
The purpose of this study is to assess the safety and tolerability of 68Ga-OPS202 used for the diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP NETs).
Healthy Participants
Dysport
United Kingdom of Great Britain and Northern Ireland (the)
Completed
A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants
Study aimed at comparing the pharmacodynamic profile (including duration of action) of three commercialized toxins by measuring the action potential of the injected muscle (extensor digitorum brevis)
Neuroendocrine Tumors
satoreotide tetraxetan
Austria
Australia
France
Canada
Denmark
United Kingdom of Great Britain and Northern Ireland (the)
Switzerland
Active, Not Recruiting
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
The purpose of the protocol is to evaluate the long-term safety of medicine 177Lu-satoreotide tetraxetan (also known as 177Lu-IPN01072 or 177Lu-OPS201) for patients who have previously received 177Lu-satoreotide tetraxetan in the clinical study OPS-C-001 / D-FR-01072-001.
Primary Biliary Cholangitis (PBC)
elafibranor
United States of America (the)
Recruiting
A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC). Participants will also have inadequate response or intolerance to ursodeoxycholic acid (UDCA). UDCA is a medication used in the management and treatment of PBC. PBC is a disease that progresses slowly. It causes damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many people with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment). Each participant will be in the study for about 7 years. The main aim of this study is to determine if elafibranor is better than placebo in preventing adverse (bad) clinical outcomes including progression of disease leading to liver transplant or death. This study will also study the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itching and tiredness.
Metastatic Castrate Resistant Prostate Cancer
tasquinimod
Germany
France
Czechia
Denmark
Lithuania
Hungary
Italy
United Kingdom of Great Britain and Northern Ireland (the)
Spain
Poland
Belgium
Terminated
A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
The purpose of this study is to confirm that tasquinimod used as maintenance therapy is active and tolerable in patients with metastatic castrate-resistant prostate cancer not progressing after a first chemotherapy with docetaxel.